Symptomatic Treatment Drug Trial Portfolio
1) Data for active Phase 1-3 PD trials was downloaded from ClinicalTrials.gov on April 15, 2021. (n=191 trials)
2) Data for "Recently Completed" Phase 1-3 PD trials was downloaded from ClinicalTrials.gov on April 15, 2021. (n=41 trials)
3) 3 studies were excluded
4) Each trial in 1) and 2) was manually classified as: "Treating symptoms", "Modifying disease progression", "Measuring disease progression", or "Understanding pathology".
5) 104 trials were identified as evaluations of therapies to treat PD symptoms. They comprise our Portfolio of Symptomatic Treatment Trials.
6) Trials in the Symptomatic Portfolio were also classified as evaluating compounds that are: novel, repurposed (approved to treat another disease or PD symptom) or reformulated.
Data compiled by PD Advocate Sue Buff, with special thanks to PD Advocate Marina Noordegraaf for input on trial classifications.
Trial classification references
ClinicalTrials.gov, scientific journals, industry/academic press releases.
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020, Journal of PD July 2020
GOAL of TRIAL PORTFOLIOS
Enable Parkinson's patients and advocates to:
Inspire hope that better treatments are on the horizon and encourage the patient voice in making this a reality.
Note: Symptom descriptors are as provided on ClinicalTrials.gov.
active & recently completed PD clinical trials, segmented by trial focus
Analyzing the Parkinson's disease clinical trial pipeline to facilitate patient collaboration in research.
Portfolio trials: motor and non-motor symptom breakout
WHAT ARE TRIAL PORTFOLIOS?
For greater clarity into the clinical trial pipeline, trials can be segmented into groups (portfolios) sharing a common trial focus or characteristic, such as disease-modification therapies (DMT), symptomatic treatments (ST), devices, gene/cell therapies, repurposed compounds, exercise, biomarkers, mechanism of action, therapeutic target, etc.
A trial portfolio contains a set of trial identifiers
(ClinicalTrials.gov NCT numbers) just as a stock portfolio can be represented by a set of stock ticker symbols, for example. Each trial ID links to information published by the trial's sponsor on the ClinicalTrials.gov registry. At any given time, a trial may be active or completed, so portfolios are time-stamped to indicate each trial's status on the date the portfolio was compiled.